Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection

Key Inclusion Criteria:

- Must have participated in a Gilead-sponsored chronic hepatitis B (CHB) study no more
than 120 days prior to Baseline (Day 1), except for participants from previous
Gilead-sponsored study number GS-US-174-0149, who will have up to one year from their
last visit in that protocol.

- Must have the ability to understand and sign a written informed consent form, which
must be obtained prior to initiation of study procedures

- Must be willing and able to comply with the visit schedule and study requirements

- Must have documented HBV DNA < 2,000 IU/mL at time of screening visit, which shall
occur no later than 1 year post last study visit in GS-US-174-0149

- Must have documented hepatitis B surface antigen (HBsAg) negative status anytime
during participation in GS-US-174-0149 regardless of ongoing HBV treatment

Key Exclusion Criteria:

- Patient participating or planning to participate in another clinical study with an
investigational agent

- History of clinically-significant illness or any other major medical disorder that may
interfere with follow-up, assessments or compliance with the protocol

- Believed by the Study Investigator to be inappropriate for study participation for any
reason not otherwise listed

- Received TDF monotherapy either as part of GS-US-174-0149 Arm C (TDF monotherapy arm)
or for TDF retreatment, and have taken any HBV antiviral therapy since completion of
GS-US-174-0149

Note: Other protocol defined Inclusion/Exclusion criteria may apply.